SOURCE: Milestone Scientific, Inc.

Milestone Scientific, Inc.

February 08, 2016 07:30 ET

Milestone Scientific's Epidural & Intra-Articular Subsidiary Announces Abstract Acceptance for Presentation at ASRA's 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting

LIVINGSTON, NJ--(Marketwired - February 08, 2016) - Milestone Scientific Inc.'s (NYSE MKT: MLSS) Epidural & Intra-Articular (IA) Subsidiary today announced that its abstract entitled "Objective Epidural Space Identification Utilizing Needle-Tip Pressure Measurement is Equivalent to Fluoroscopy/LOR" has been accepted for the American Society of Regional Anesthesia and Pain Medicine's (ASRA) 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting taking place March 31 through April 2, 2016 in New Orleans.

First author, Dr. Ralf Gephard, MD, has been invited to present the findings of the Company's prospective, open labeled, clinical trial assessing the CompuFlo® technology during a moderated e-poster session. According to ASRA, only the highest scoring abstracts are selected for moderated sessions. The abstract will be published in the Journal of Regional Anesthesia & Pain Medicine that will coincide with the meeting.

Milestone's Epidural & Intra-Articular (IA) Subsidiary designed the study in conjunction with its Scientific Advisory Board, and in agreement with the U.S. Food and Drug Administration (FDA), to assess the safety and effectiveness of the pressure sensing technology in identification of the epidural space.

Leonard Osser, Chief Executive Officer of Milestone Scientific, commented, "We are pleased to announce the acceptance of our abstract in the Journal of Regional Anesthesia & Pain Medicine and look forward to presenting the findings at the prestigious ASRA 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting."

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a medical R&D company that designs, patents, incubates and commercializes a growing portfolio of innovative injection technologies. Milestone's computer-controlled systems make injections precise, efficient, and virtually painless. For more information please visit our website:

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2014. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact Information

  • Contact:
    David Waldman or Natalya Rudman
    Crescendo Communications, LLC
    Tel: 212-671-1020